Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2014 1
2015 1
2016 1
2017 6
2018 8
2019 10
2020 9
2021 11
2022 10
2023 9
2024 5

Text availability

Article attribute

Article type

Publication date

Search Results

61 results

Results by year

Filters applied: . Clear all
Page 1
Sacituzumab govitecan in metastatic triple-negative breast cancer patients treated at Institut Curie Hospitals: efficacy, safety, and impact of brain metastases.
De Moura A, Loirat D, Vaillant S, Korbi S, Kiavue N, Bello Roufai D, Escalup L, Desmaris R, Vaflard P, Cottu P, Pierga JY, Bidard FC, Cabel L, Acramel A. De Moura A, et al. Among authors: cabel l. Breast Cancer. 2024 Apr 10. doi: 10.1007/s12282-024-01565-7. Online ahead of print. Breast Cancer. 2024. PMID: 38600429
Overall Survival With Circulating Tumor Cell Count-Driven Choice of Therapy in Advanced Breast Cancer: A Randomized Trial.
Bidard FC, Kiavue N, Jacot W, Bachelot T, Dureau S, Bourgeois H, Goncalves A, Brain E, Ladoire S, Dalenc F, Gligorov J, Teixeira L, Emile G, Ferrero JM, Loirat D, Cabel L, Kadi A, Diéras V, Alix-Panabières C, Pierga JY. Bidard FC, et al. Among authors: cabel l. J Clin Oncol. 2024 Feb 1;42(4):383-389. doi: 10.1200/JCO.23.00456. Epub 2023 Nov 6. J Clin Oncol. 2024. PMID: 37931185 Clinical Trial.
[18F]FDG PET/CT for predicting triple-negative breast cancer outcomes after neoadjuvant chemotherapy with or without pembrolizumab.
Seban RD, Arnaud E, Loirat D, Cabel L, Cottu P, Djerroudi L, Hescot S, Loap P, Bonneau C, Bidard FC, Huchet V, Jehanno N, Berenbaum A, Champion L, Buvat I. Seban RD, et al. Among authors: cabel l. Eur J Nucl Med Mol Imaging. 2023 Nov;50(13):4024-4035. doi: 10.1007/s00259-023-06394-y. Epub 2023 Aug 22. Eur J Nucl Med Mol Imaging. 2023. PMID: 37606858
Epigenomic mapping identifies an enhancer repertoire that regulates cell identity in bladder cancer through distinct transcription factor networks.
Neyret-Kahn H, Fontugne J, Meng XY, Groeneveld CS, Cabel L, Ye T, Guyon E, Krucker C, Dufour F, Chapeaublanc E, Rapinat A, Jeffery D, Tanguy L, Dixon V, Neuzillet Y, Lebret T, Gentien D, Davidson I, Allory Y, Bernard-Pierrot I, Radvanyi F. Neyret-Kahn H, et al. Among authors: cabel l. Oncogene. 2023 May;42(19):1524-1542. doi: 10.1038/s41388-023-02662-1. Epub 2023 Mar 22. Oncogene. 2023. PMID: 36944729 Free PMC article.
61 results